Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
复制标题
DOI：
10.1038/bjc.1989.200
复制
发表时间：
1989-06
影响因子：
8.8
通讯作者：
Nicholson, R I
中科院分区：
文献类型：
--
作者：
Bouzubar, N;Walker, K J;Griffiths, K;Ellis, I O;Elston, C W;Robertson, J F;Blamey, R W;Nicholson, R I
对136例乳腺癌进行了Ki67免疫组织化学染色，并与乳腺癌的临床和病理特征进行了比较。染色最常见于分化较低的肿瘤，表现出较高的核分裂活性，但与肿瘤大小、淋巴结状况和ER表达无关。Ki67高表达常与乳腺癌术后早期复发有关。这些数据与Ki67抗体检测与细胞增殖密切相关的抗原的概念是一致的，从而为肿瘤的这一重要特征提供了一个临床上有用的标记。
Ki67 immunostaining has been performed on 136 primary breast cancers and related to various clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this important characteristic of the tumour.